| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | GeneticVariation | disease | BEFREE | A high CD34+/CD38- cell burden at diagnosis associated with worse genetic risk and secondary AML. | 28133783 | 2017 | ||||
|
0.070 | Biomarker | disease | BEFREE | Previously, we reported that the Fas death receptor, while overexpressed in low-risk myelodysplastic syndromes (MDS), becomes undetectable on CD34(+) progenitors when the disease progresses to secondary acute myeloid leukemia (AML). | 23604035 | 2013 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | This is the first report showing that high levels of Survivin and Aurora-B kinase expression in CD34(+) cells are distinctive molecular features of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia following myelodysplastic syndrome. | 22419576 | 2012 | ||||
|
0.070 | GeneticVariation | disease | BEFREE | Age, percentage of CD34-positive blasts, FLT3-ITD mutant-to-wild-type ratio, cytogenetic risk, and de-novo or secondary AML were identified as independent prognostic factors, and included in the PRT score. | 22197676 | 2012 | ||||
|
0.070 | Biomarker | disease | BEFREE | In addition, SHIP1 reduced the autonomous proliferation of CD34(+) cells from a patient with a secondary AML who had a very high peripheral blast count (300 x 10(9) l(-1)). | 19148132 | 2009 | ||||
|
0.070 | Biomarker | disease | BEFREE | No significant differences in age, sex, leukocyte count, French-American-British subtype, or karyotype group were found. c-mpl+ patients more commonly had secondary AML (41% v 11%; P = .046) and more commonly expressed CD34 (67% v 12%; P = .0004). | 9196139 | 1997 | ||||
|
0.070 | AlteredExpression | disease | BEFREE | In order to analyze the correlations between the clinicopathologic features, cytogenetic and CD34 expression in AML, we retrospectively investigated 99 patients with newly diagnosed AML: 85 with de novo disease and 14 with secondary AML (SAML). | 8895688 | 1996 |